Please login to the form below

Vyndaqel

This page shows the latest Vyndaqel news and features for those working in and with pharma, biotech and healthcare.

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.

Latest news

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status. Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for ... Prior to Vyndaqel, treatment options for patients with ATTR
Vyndaqel a bright spot as Pfizer comes under pressure

The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier ... As of the end of 2019 more than 9, 000 ATTR
Alnylam gains key NICE approval for Onpattro

decision. The two rivals also face competition from Pfizer’s Vyndaqel (tafadamis). It has been available in Europe for a number of years as a polyneuropathy treatment, but recently gained US ... The company also highlighted the fact that around a third
Pfizer buys dwarfism drug company Therachon for $810m

The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
Speedy approval for Pfizer's Onpattro rival

Both Vyndamax and Vyndaqel are expected to reduce cardiovascular mortality by 30% and cut cardiovascular related hospitalisation by 32%, strong claims which will help fuel their uptake. ... Vyndaqel has been priced at $225, 000 per year, half the price

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

produced impressive data for its Vyndaqel (tafamidis). ... Vyndaqel has been available in Europe since 2011 for Transthyretin (TTR) amyloid polyneuropathy, but isn’t yet approved in the US.
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive

Healthcare Lead Copywriter: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...